These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39113695)

  • 1.
    He Y; Liu Y; Gong J; Yang F; Sun C; Yan X; Duan N; Hua Y; Zeng T; Fu Z; Liang Y; Li W; Huang X; Tang J; Yin Y
    Int J Biol Sci; 2024; 20(10):3923-3941. PubMed ID: 39113695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling.
    Prentzell MT; Rehbein U; Cadena Sandoval M; De Meulemeester AS; Baumeister R; Brohée L; Berdel B; Bockwoldt M; Carroll B; Chowdhury SR; von Deimling A; Demetriades C; Figlia G; ; de Araujo MEG; Heberle AM; Heiland I; Holzwarth B; Huber LA; Jaworski J; Kedra M; Kern K; Kopach A; Korolchuk VI; van 't Land-Kuper I; Macias M; Nellist M; Palm W; Pusch S; Ramos Pittol JM; Reil M; Reintjes A; Reuter F; Sampson JR; Scheldeman C; Siekierska A; Stefan E; Teleman AA; Thomas LE; Torres-Quesada O; Trump S; West HD; de Witte P; Woltering S; Yordanov TE; Zmorzynska J; Opitz CA; Thedieck K
    Cell; 2021 Feb; 184(3):655-674.e27. PubMed ID: 33497611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
    Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y
    Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasputin a decade on and more promiscuous than ever? A review of G3BPs.
    Alam U; Kennedy D
    Biochim Biophys Acta Mol Cell Res; 2019 Mar; 1866(3):360-370. PubMed ID: 30595162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
    Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
    FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
    Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
    Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
    Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
    Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance.
    White CD; Li Z; Dillon DA; Sacks DB
    J Biol Chem; 2011 Aug; 286(34):29734-47. PubMed ID: 21724847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G3BP1 and G3BP2 regulate translation of interferon-stimulated genes: IFITM1, IFITM2 and IFITM3 in the cancer cell line MCF7.
    Alam U; Kennedy D
    Mol Cell Biochem; 2019 Sep; 459(1-2):189-204. PubMed ID: 31172368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer.
    Nami B; Wang Z
    Cells; 2024 Aug; 13(17):. PubMed ID: 39273024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
    Sethunath V; Hu H; De Angelis C; Veeraraghavan J; Qin L; Wang N; Simon LM; Wang T; Fu X; Nardone A; Pereira R; Nanda S; Griffith OL; Tsimelzon A; Shaw C; Chamness GC; Reis-Filho JS; Weigelt B; Heiser LM; Hilsenbeck SG; Huang S; Rimawi MF; Gray JW; Osborne CK; Schiff R
    Mol Cancer Res; 2019 Nov; 17(11):2318-2330. PubMed ID: 31420371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Chikungunya nsP3 in Regulating G3BP1 Activity, Stress Granule Formation and Drug Efficacy.
    Lu X; Alam U; Willis C; Kennedy D
    Arch Med Res; 2021 Jan; 52(1):48-57. PubMed ID: 33131924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
    Park M; Jung E; Park JM; Park S; Ko D; Seo J; Kim S; Nam KD; Kang YK; Farrand L; Hoang VH; Nguyen CT; La MT; Nam G; Park HJ; Ann J; Lee J; Kim YJ; Kim JY; Seo JH
    Theranostics; 2024; 14(6):2442-2463. PubMed ID: 38646654
    [No Abstract]   [Full Text] [Related]  

  • 16. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
    Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
    Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-Resistant HER2
    Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
    Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation.
    Han M; Gu Y; Lu P; Li J; Cao H; Li X; Qian X; Yu C; Yang Y; Yang X; Han N; Dou D; Hu J; Dong H
    Mol Cancer; 2020 Feb; 19(1):26. PubMed ID: 32020881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.